| 丁晓欢,张天舒,栾 佳,吕 静,张 君.黄芪颗粒剂联合厄贝沙坦对IgA肾病患者肾功能、炎性因子及免疫功能的影响[J].,2020,(20):3919-3922 |
| 黄芪颗粒剂联合厄贝沙坦对IgA肾病患者肾功能、炎性因子及免疫功能的影响 |
| Effect of Astragalus Granule Combined with Irbesartan on Renal Function, Inflammatory Factors and Immune Function in IgA Nephropathy |
| 投稿时间：2020-04-22 修订日期：2020-05-18 |
| DOI：10.13241/j.cnki.pmb.2020.20.026 |
| 中文关键词: 黄芪颗粒剂 厄贝沙坦 IgA肾病 肾功能 炎性因子 免疫功能 |
| 英文关键词: Astragalus granule Irbesartan Immunoglobulin A nephropathy Renal function Inflammatory factor Immune function |
| 基金项目:辽宁省科学技术计划项目（20120620） |
|
| 摘要点击次数: 637 |
| 全文下载次数: 284 |
| 中文摘要: |
| 摘要 目的：探讨黄芪颗粒剂联合厄贝沙坦对IgA肾病（IgAN）患者肾功能、炎性因子及免疫功能的影响。方法：回顾性分析2016年3月~2019年8月期间于我院就诊的98例IgAN患者的临床资料，根据用药方案的不同将患者分为对照组（n=49）和治疗组（n=49），对照组予以厄贝沙坦治疗，治疗组在对照组的基础上联合黄芪颗粒剂治疗，比较两组患者疗效、肾功能、炎性因子及免疫功能，记录两组治疗期间不良反应情况。结果：治疗组治疗2个月后的临床总有效率为91.84%（45/49），高于对照组的73.47%（36/49）（P<0.05）。治疗2个月后，两组白细胞介素-6（IL-6）、超敏C-反应蛋白（hs-CRP）、肿瘤坏死因子-α（TNF-α）均较治疗前下降，且治疗组低于对照组（P<0.05）。两组不良反应发生率比较无差异（P>0.05）。治疗2个月后，两组24 h尿蛋白定量（24h-Upro）、血肌酐（Scr）、尿素氮（BUN）均较治疗前下降，且治疗组低于对照组（P<0.05）。治疗2个月后，两组CD4+/CD8+、CD4+较治疗前下降，且治疗组低于对照组（P<0.05）；CD8+较治疗前升高，且治疗组高于对照组（P<0.05）。结论：黄芪颗粒剂联合厄贝沙坦治疗IgAN患者，疗效确切，可有效改善患者肾功能、免疫功能，降低炎性因子水平，且安全可靠。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of Astragalus granule combined with irbesartan on renal function, inflammatory factors and immune function in patients with IgA nephropathy (IgAN). Methods: The clinical data of 98 patients with IgAN from March 2016 to August 2019 were analyzed retrospectively, the patients were divided into control group (n=49) and treatment group (n=49) according to different medication plans. The control group was treated with irbesartan. The treatment group was treated with Astragalus granule on the basis of the control group. The curative effect, renal function, inflammatory factor and immune function of the two groups were compared. Adverse reactions during treatment in both groups were recorded. Results: The total effective rate of the treatment group at 2 months after treatment was 91.84% (45/49), which was higher than 73.47% (36/49) of the control group(P<0.05). 2 months after treatment, the levels of high sensitive interleukin-6(IL-6), C-reactive protein (hs-CRP), tumor necrosis factor-α(TNF-α) of the two groups were lower than those before treatment, those of the treatment group were lower than those of the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). 2 months after treatment, 24h urine protein quantity (24h-Upro), blood creatinine (Scr) and urea nitrogen (BUN) of the two groups were lower than those before treatment, and the treatment group was lower than the control group(P<0.05). 2 months after treatment, CD4+/CD8+, CD4+ of the two groups decreased compared with those before treatment, and the treatment group was lower than the control group(P<0.05). CD8+ was higher than that before treatment, and the treatment group was higher than the control group(P<0.05). Conclusion: Astragalus granule combined with irbesartan in the treatment of patients with IgAN, the effect is accurate, which can effectively improve the renal function, immune function, reduce the level of inflammatory factors, and it is safe and reliable. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
